Physician profile
Nancy Coles
NPI 1609868074
$2,311.19
in general payments reported to CMS, 2019-2025
20 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $203 · 2021: $403 · 2022: $366 · 2023: $179 · 2024: $394 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.42 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $625.56 | 2019-2022 | |
| Alcon Vision LLC | $432.64 | 2019-2024 | Simbrinza |
| Johnson & Johnson Surgical Vision, INC. | $134.31 | 2025 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $133.14 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Omeros Corporation | $125.00 | 2019 | |
| Glaukos Corporation | $120.16 | 2020 | |
| Ivantis, INC | $105.27 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $98.05 | 2024 | Xdemvy |
| Abbvie INC. | $86.19 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $83.60 | 2019-2023 | Cequa |
| Rxsight INC | $78.13 | 2021 | |
| Allergan, INC. | $54.86 | 2020 | |
| Thea Pharma INC. | $44.92 | 2022-2023 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.68 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $34.90 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $34.40 | 2021 | |
| Oyster Point Pharma, INC. | $33.63 | 2023 | Tyrvaya |
| Harrow Eye, LLC | $22.12 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $13.45 | 2022 | |
| Eyevance Pharmaceuticals LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Coles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.